[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BioCentury BioCentury
BioCentury posts on X about $8b, tariffs, $novo, $bmy the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +85%
- X Month XXXXXX +27%
- X Months XXXXXXX +64%
- X Year XXXXXXX +3.30%
Mentions: X #
- X Week XX +30%
- X Month XX +3.10%
- X Months XXX -XX%
- X Year XXX -XXXX%
Followers: XXXXXX #
- X Week XXXXXX +0.10%
- X Month XXXXXX +0.34%
- X Months XXXXXX +2.10%
- X Year XXXXXX +2.70%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXX% finance XXXX% travel destinations XXXX%
Social topic influence $8b 1.75%, tariffs 0.88%, $novo 0.88%, $bmy 0.88%, novo 0.88%, $4503t 0.88%, hong kong 0.88%, sana 0.88%, caps 0.88%, tau XXXX%
Top accounts mentioned or mentioned by @jeff_cranmer @steveusdin1 @fishburnsimone @stephenphansen @usfda @jeffcranmer @daniellegolovin @insilicotrials @moneyoverhealth @bsbhbyvt @vitaltransform @genmabs @gsks @cidaratheras @sofinnovavcs @nvidia @novonordisks @biobonanos @jeitolife @usfdas
Top assets mentioned Bristol-Myers Squibb Co (BMY)
Top Social Posts #
Top posts by engagements in the last XX hours
"On the latest #BioCenturyThisWeek podcast @Genmabs $8B takeout of Merus @GSKs CEO switch and U.S. drug pricing tariffs and more -- with @FishburnSimone @SteveUsdin1 @StephenPHansen @Jeff_Cranmer"
X Link @BioCentury 2025-09-30T01:30Z 16.4K followers, XXX engagements
"AstraZeneca MFN deal similar to @Pfizer's raises questions for the entire industry"
X Link @BioCentury 2025-10-14T01:00Z 16.4K followers, XXX engagements
"On the latest #BioCenturyThisWeek podcast: 4Q biotech public market outlook Biosecure returns & big time biotech M&A with @StephenPHansen @SteveUsdin1 @FishburnSimone @Jeff_Cranmer $NOVO $BMY"
X Link @BioCentury 2025-10-14T00:30Z 16.4K followers, XXX engagements
"Arcus data throw TIGIT a lifeline. Plus: Tvardi falls on IPF miss Astellas CLDN18.2 mAb misses expansion opportunity and more: in BioCentury's Clinical Report"
X Link @BioCentury 2025-10-15T23:00Z 16.4K followers, XXX engagements
"In BioCentury's Public Equity Report: Zenas' PIPE supports a deal with a China-based biotech; Apogee priced a follow-on at a premium; the latest in Hong Kong listings; and more"
X Link @BioCentury 2025-10-10T21:00Z 16.4K followers, XXX engagements
"Synconas Yellowstone names Sana co-founder Jim MacDonald CEO. Plus:Pease leavingCharles River as CFO and updates fromAchieve andALX"
X Link @BioCentury 2025-09-17T00:00Z 16.4K followers, XXX engagements
"BioCentury's Deals Report: Genmabs $8B takeout caps week of modest dealmaking. Hengrui Gilead Merck all enter licensing deals"
X Link @BioCentury 2025-09-30T00:30Z 16.4K followers, XXX engagements
"BioCentury's roundup of translational news includes two epigenetic modulators with therapeutic potential an ER enzyme target for clearing tau aggregates and the use of intrinsically disordered regions to enhance CAR signaling"
X Link @BioCentury 2025-10-15T20:30Z 16.4K followers, XXX engagements
"With clinical proof-of-concept in multiple indications a spate of deals and a growing pipeline BBB shuttles may soon come of age. BioCentury analyzes the technologies beyond BBB shuttle therapies and their near and longer applications"
X Link @BioCentury 2025-10-15T00:30Z 16.4K followers, XXX engagements
"NICE poised to raise cost-per-QALY threshold"
X Link @BioCentury 2025-10-15T01:00Z 16.4K followers, XXX engagements